We are also excited about the progress last year in new clinical development efforts. Despite pandemic-related obstacles, we opened important trials: Phase 3 trial in patients with metastatic pancreatic cancer, a Phase 1b trial in patients with advanced adrenal cancer, a second Phase 2 trial in patients with the antipsychotic induced weight gain, and a Phase 2 trial in patients with NASH. We also continued to advance new selective cortisol modulators. One such compound, CORT113176, has shown promise in animal models of ALS. We plan to evaluate it in a Phase 2 trial, beginning in the fourth quarter of 2021. As I've said before, I do not know any company of Corcept's size that combines commercial success with such diverse and promising clinical activities.